SCHEMBL5886828

SCHEMBL5886828

COc1ccc(NC(=O)c2ccc(-n3c(=O)ccc4c(C)nc(N5CCc6ccccc6C5)nc43)cc2)cc1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 5/20 0.49
KMT2A Q03164 3/20 0.44
ADAMTS4 O75173 1/20 0.44
MAPT P10636 5/20 0.43
ALDH1A1 P00352 4/20 0.43
USP2 O75604 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
LMNA P02545 1/20 0.43
HPGD P15428 1/20 0.43
HSD17B10 Q99714 1/20 0.43
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
POLB P06746 1/20 0.42
TAAR1 Q96RJ0 1/20 0.42
MEN1 O00255 2/20 0.41
PKM P14618 1/20 0.40
KDM4E B2RXH2 1/20 0.40
AURKA O14965 1/20 0.40
RPS6KB1 P23443 1/20 0.40
AURKB Q96GD4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5886800 0.88 NOD1 (0.50) KMT2AMAPTALDH1A1USP2SMN1; SMN2
SCHEMBL5886832 0.88 NAMPT (0.49) NAMPTADAMTS4MAPTALDH1A1SMN1; SMN2
SCHEMBL5886733 0.88 MAPT (0.55) KMT2AMAPTALDH1A1USP2SMN1; SMN2
SCHEMBL5886740 0.86 NOD1 (0.53) KMT2AMAPTALDH1A1SMN1; SMN2LMNA
SCHEMBL5886977 0.85 MAPT (0.47) KMT2AMAPTALDH1A1USP2SMN1; SMN2
SCHEMBL5886784 0.84 NAMPT (0.47) NAMPTADAMTS4MAPTROCK2TP53
SCHEMBL5886722 0.81 RXRA (0.46) ADAMTS4MAPTALDH1A1PKMKDM4E
SCHEMBL5887057 0.81 DRD2 (0.41) ADAMTS4MAPTSMN1; SMN2LMNANPC1
SCHEMBL5887072 0.81 ALDH1A1 (0.40) ADAMTS4MAPTALDH1A1NPC1RAB9A
SCHEMBL5887156 0.80 ADAMTS4 (0.43) ADAMTS4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US claimed
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors PHARMACIA ITALIA S.P.A. 2004-01-15 US claimed
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US disclosed
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors PHARMACIA ITALIA S.P.A. 2004-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors TERT, TERF2, TERF2IP NAMPT 527/4885KMT2A 1530/4885ADAMTS4 2688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.